Claims for Patent: 6,610,545

Summary for Patent: 6,610,545

Title:	Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
Abstract:	An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
Inventor(s):	Dujon; Bernard (Gif sur Yvette, FR), Choulika; Andre (Paris, FR), Colleaux; Laurence (Edinburgh, GB), Fairhead; Cecile (Malakoff, FR), Perrin; Arnaud (Paris, FR), Plessis; Anne (Paris, FR), Thierry; Agnes (Paris, FR)
Assignee:	Institut Pasteur (Paris, FR) University Paris VI (Paris, FR)
Application Number:	09/836,169
Patent Claims:	1. A method for in vivo site directed genetic recombination in an organism comprising: (a) providing a transgenic cell having at least one HO endonuclease recognition site inserted at a unique location in a chromosome; (b) providing an expression vector that expresses said endonuclease in said transgenic cell; (c) providing a plasmid comprising a gene of interest and a DNA sequence homologous to the sequence of the chromosome, allowing homologous recombination; (d) transfecting said transgenic cell with said plasmid of step (c); (e) expressing said endonuclease from said expression vector in said cell; and (f) cleaving said HO endonuclease recognition site with said endonuclease, whereby said cleavage promotes the insertion of said gene of interest into said chromosome of said organism at a specific site by homologous recombination. 2. The method of claim 1, wherein said endonuclease recognition site has been introduced into said cell by homologous recombination. 3. The method of claim 1, wherein said endonuclease recognition site has been introduced into said cell by retroviral insertion. 4. The method of claim 1, wherein said organism is yeast. 5. The method of claim 1, wherein said organism is bacteria. 6. The method of claim 1, wherein said organism is a mammal. 7. A method for in vivo site directed genetic recombination in an organism comprising: (a) providing a transgenic cell having at least one Group I intron encoded endonuclease recognition site inserted at a unique location in a chromosome; (b) providing an expression vector that expresses said endonuclease in said transgenic cell; (c) providing a plasmid comprising a gene of interest and a DNA sequence homologous to the sequence of the chromosome, allowing homologous recombination; (d) transfecting said transgenic cell with said plasmid of step (c); (e) expressing said endonuclease from said expression vector in said cell; and (f) cleaving said at least one Group I intron encoded endonuclease recognition site with said endonuclease, whereby said cleavage promotes the insertion of said gene of interest into said chromosome of said organism at a specific site by homologous recombination. 8. The method of claim 7, wherein said endonuclease recognition site has been introduced into said cell by homologous recombination. 9. The method of claim 7, wherein said endonuclease recognition site has been introduced into said cell by retroviral insertion. 10. The method of claim 7, wherein said organism is yeast. 11. The method of claim 7, wherein said organism is bacteria. 12. The method of claim 7, wherein said organism is a mammal. 13. The method of claim 7, wherein said endonuclease recognition site is selected from the group consisting of Class I I-endonuclease sites, Class II I-endonuclease sites, Class III I-endonuclease sites, Class IV I-endonuclease sites, and Class V I-endonuclease sites. 14. The method of claim 13, wherein said endonuclease recognition site is a Class I I-endonuclease site. 15. The method of claim 14, wherein said endonuclease recognition site is selected from the group consisting of I-SceI, I-SceIV, I-CsmI, and I-PanI sites. 16. The method of claim 15, wherein said endonuclease recognition site is an I-SceI site. 17. The method of claim 7, wherein said endonuclease recognition site is an I-SceIV site. 18. The method of claim 7, wherein said endonuclease recognition site is an I-Csml site. 19. The method of claim 7, wherein said endonuclease recognition site is an I-PanI site. 20. The method of claim 7, wherein said endonuclease recognition site is an I-SceII site. 21. The method of claim 7, wherein said endonuclease recognition site is an I-CeuI site. 22. The method of claim 7, wherein said endonuclease recognition site is an I-PpoI site. 23. The method of claim 7, wherein said endonuclease recognition site is an I-SceIII site. 24. The method of claim 7, wherein said endonuclease recognition site is an I-Crel site. 25. The method of claim 7, wherein said endonuclease recognition site is an I-TevI site. 26. The method of claim 7, wherein said endonuclease recognition site is an I-TevII site. 27. The method of claim 7, wherein said endonuclease recognition site is an I-TevIII site.

Details for Patent 6,610,545

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2012-05-05
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2012-05-05
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2012-05-05